| Literature DB >> 22179167 |
Tatiana Maria Folador Mattioli1, Silvana da Silva, Ana Maria Trindade Grégio, Maria Ângela Naval Machado, Antônio Adilson Soares de Lima, Luciana Reis Azevedo Alanis.
Abstract
OBJECTIVES: To evaluate the effects of antidepressants and pilocarpine on the quantity of myoepithelial cells and on the proliferation index of the epithelial cells of rat parotid glands.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22179167 PMCID: PMC3164412 DOI: 10.1590/s1807-59322011000900017
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Control and experimental groups according to the drugs used.
| Group | N | Drugs | Period of treatment (days) | Dose | Administration |
| 1- C30 | 10 | Saline | 1-30 | 0.1 mL | Intraperitoneal |
| 2- C60 | 10 | Saline | 1-60 | 0.1 mL | Intraperitoneal |
| 3- Pilo | 10 | Pilocarpine | 1-60 | 0.05 mL | Topical |
| 4- F30 | 10 | Fluoxetine | 1-30 | 20 mg/kg | Intramuscular |
| 5- V30 | 10 | Venlafaxine | 1-30 | 40 mg/kg | Intramuscular |
| 6- FS60 | 10 | Fluoxetine | 1-30 | 20 mg/kg | Intramuscular |
| Saline | 31-60 | 0.1 mL | Intraperitoneal | ||
| 7- VS60 | 10 | Venlafaxine | 1-30 | 40 mg/kg | Intramuscular |
| Saline | 31-60 | 0.1 mL | Intraperitoneal | ||
| 8- FP60 | 10 | Fluoxetine | 1-30 | 20 mg/kg | Intramuscular |
| Fluoxetine + Pilocarpine | 31-60 | 20 mg/kg/0.05 mL | Intramuscular and Topical | ||
| 9- VP60 | 10 | Venlafaxine | 1-30 | 40 mg/kg | Intramuscular |
| Venlafaxine + Pilocarpine | 31-60 | 40 mg/kg/0.05 mL | Intramuscular and Topical |
N = sample size.
Gel base prepared with 1% pilocarpine hydrochloride (Gerbras Química e Farmacêutica Ltda., São Paulo, Brazil).
Injectable fluoxetine (20040625, Galena Química e Farmacêutica Ltda., Campinas, Brazil).
Injectable venlafaxine (D/VN/002/02, Galena Química e Farmacêutica Ltda., Campinas, Brazil).
Mean values (X) and standard deviations (SD) of the studied variables in the groups treated for 30 days with saline (C30), fluoxetine (F30), or venlafaxine (V30).
| Groups | C30 | F30 | V30 | ||||
| X | SD | X | SD | X | SD | ||
| SSFR (mL/min) | 0.051±0.026 | 0.014 ± 0.006 | 0.026 ± 0.022 | 0.001 | |||
| CV (mm3) | 6,965.683±3,792.951 | 10,384.311±4,869.539 | 11,945.927±7,891.179 | 0.000 | |||
| PCNA | 55.8±14.382 | 59.4±16.900 | 89.5±16.400 | 0.000 | |||
| C | 13.9±2.644 | 20±4.216 | 19.8±5.007 | 0.003 | |||
Values obtained from the study by da Silva et al. (2009)15.
SSFR – stimulated salivary flow rate; CV – cellular volume; PCNA – proliferating cell nuclear antigen; C – calponin.
Groups followed by the same letter differed statistically from each other.
Statistically significant difference among groups (p<0.05).
Mean values (X) and standard deviations (SD) of the studied variables in the groups treated for 60 days with saline (C60), pilocarpine (Pilo), fluoxetine and saline (FS60), venlafaxine and saline (VS60), fluoxetine and pilocarpine (FP60), or venlafaxine and pilocarpine (VP60).
| Groups | C60 | PILO | FS60 | VS60 | FP60 | VP60 | |||||||
| X | SD | X | SD | X | SD | X | SD | X | SD | X | SD | ||
| SSFR (mL/min) | 0.052±0.029 | 0.067±0.028 | 0.036±0.017 | 0.020±0.004 | 0.034±0.014 | 0.055± 0.026 | 0.000 | ||||||
| CV (mm3) | 6,505.564± 3,343.475 | 5,825.418±1,968.070 | 6,809.347±3,189.246 | 7,525.112±3,196.085 | 7,519.797±4,272.808 | 10,194.315±4,456.345 | 0.000 | ||||||
| PCNA | 50±17.531 | 46.8±13.506 | 36.7±16.687 | 52.5±18.710 | 52±17.153 | 43.6±18.007 | 0.296 | ||||||
| C | 13.6±4.789 | 22.1±7.385 | 24.2±7.955 | 19.7±4.322 | 7±1.563 | 18.2±6.250 | 0.000 | ||||||
Values obtained from the study by da Silva et al. (2009)15.
SSFR – stimulated salivary flow rate; CV – cellular volume; PCNA – proliferating cell nuclear antigen; C – calponin.
Groups followed by the same letter differed statistically from each other.
Statistically significant difference among the groups (p<0.05).
– No statistically significant difference among the groups (p>0.05).
Figure 1Rat parotid gland with normal parenchyma. Immunohistochemical staining of PCNA on epithelial cells (C60, original magnification 400X).
Figure 4Immunohistochemical staining of calponin on myoepithelial cells (V30, original magnification 400X).